Small Molecule Kinase Inhibitors for the Potential Treatment of Down's Syndrome and Alzheimer's Disease and for Studies of Alternate Gene Splicing
Lead Inventor: Craig Thomas (NCATS)
Ref. No.: E-230-2009/0
Abstract: NIH investigators have discovered a series of potent, selective small molecule inhibitors of cdc2-like kinases (Clk) and dual-specificity tyrosine-regulated kinase 1A (Dyrk1A) with potential as modulators of gene splicing and for the treatment of Down's syndrome and Alzheimer's disease.
Potent and Selective Small Molecule Inhibitors of Specific Isoforms of Cdc2-like Kinases (Clk) and Dual Specificity Tyrosine-Phosphorylation-Regulated Kinases (Dyrk) • Bioorganic & Medicinal Chemistry Letters • May 2011 • NCATS Chemical Genomics Center
Evaluation of Substituted 6-arylquinazolin-4-amines as Potent and Selective Inhibitors of Cdc2-like Kinases (Clk) • Bioorganic & Medicinal Chemistry Letters • December 2009 • NCATS Chemical Genomics Center